Analysis of crypt cell proliferation in coeliac disease using MI-B1 antibody shows an increase in growth fraction

R Przemioslo, N A Wright, G Elia, P J Ciclitira

Abstract
This study aimed to investigate the pattern of cellular proliferation and to calculate the growth fraction of small intestinal crypts in 24 patients – eight with untreated coeliac disease (CD), six with treated CD, and 10 controls with normal villous architecture. Duodenal biopsy specimens were stained with MI-B1 antibody using an immunoperoxidase method. Positive stained crypt cells were counted and their position within each intact crypt column was noted. These were used to construct proliferation index distribution curves for each cell position from which the crypt growth fraction for each group of patients was calculated. The crypt growth fraction was found to be higher in the untreated CD group (0.57) than in the treated patients (0.39) and the controls (0.44). The mean (SEM) proliferative index for each crypt was significantly higher in the untreated group (42.3 (10.8)%; p<0.05) than in the treated CD (21.7 (8.5)%) and control (19.7 (7.5)%) groups and correlated closely with the surface:volume index and enterocyte cell height measurements in all three groups. An increased growth fraction may contribute to other changes in crypt cell kinetics to produce the histological changes seen in untreated CD.

(Gut 1995; 36: 22–27)

Keywords: coeliac disease, immunohistochemistry, crypt cell proliferation.

Coeliac disease (CD) is an inflammatory small bowel enteroopathy which responds to the withdrawal of dietary gluten. There is an increased long term risk of gastrointestinal malignancy, including small bowel carcinoma, with this disorder. This risk is greater in men with CD and in those patients who do not closely adhere to treatment with a gluten free diet.1 The histological appearance in untreated CD is of an atrophic mucosa together with elongation and hyperplasia of the crypts. Enterocytes lose their normal columnar appearance and become cuboidal.2 It has been proposed that these histological appearances are caused by changes in the mucosal immune microenvironment created by the secretion of abnormal amounts of biologically active mediators from cells involved in the cell mediated response to gluten. These may affect crypt cell proliferation and epithelial cell toxicity by different pathways.

The monoclonal antibody MI-B1 was developed in the Institute of Pathology, Kiel University, Germany.3 It is a murine IgG antibody which recognises a nuclear antigen consisting of 395 kDa and 345 kDa parts. Staining with MI-B1 increases through the cell cycle from G1 to G2 but sharply reduces after mitosis and is totally absent in Go. It has been shown by western blotting that MI-B1 recognises the same antigen as Ki-67 and therefore stains cells in all parts of the cell cycle.4

Previously, Ki-67 work was only possible on frozen sections as the epitope which the antibody recognises is concealed by tissue fixation. MI-B1 recognises the Ki-67 antigen equally well in microwaved formalin fixed and wax embedded sections as in frozen sections.5 6 The advantage of using MI-B1 is that it allows the study of archive material with better preservation of morphology within the tissues studied allowing a more accurate assessment of parameters such as the enterocyte cell height and surface:volume index (S:V) which are indicators of toxicity in coeliac disease mucosa.7

Within the small bowel, crypt cell division is thought to originate from pluripotent stem cells which are located in the basal portion8 passing through the middle or proliferative zone of the crypt and emerging near the mouth of the crypt as functional non-proliferating cells. With the onset of the inflammatory process, it has been suggested that the proliferative compartment may expand to occupy a larger part of the crypt, however, previous attempts at estimating crypt growth fraction by identifying cells in mitosis showed a reduction of the growth fraction in untreated CD crypts.

Our aim was to study the change in the crypt growth fraction in coeliac disease mucosa, to see how this varies on treatment with a gluten free diet, and the relation between total crypt labelling index and other known markers of toxicity in this disease. Taken together with other data on crypt cell kinetics, the results will help us to understand the mechanisms by which the characteristic mucosal lesion develops. The results may be of help as a baseline study for investigating the role of individual cytokines and growth factors in causing this lesion. An estimate of growth fraction using MI-B1
Analysis of cell proliferation in coeliac disease using MI-B1 antibody shows an increase in growth fraction

Figure 1: Method of sequential counting of cells within a crypt. Cells were counted in the left column of longitudinally cut crypts from the base which was designated cell position 1. The number of cells counted along this length was divided into thirds which approximated to the lower (stem cell), middle (proliferative) and upper (maturation) compartments. Enterocyte cell height was taken as a linear measurement from the basement membrane to the surface of the cell as shown.

provides new information as this will identify all cells in the cell cycle rather than only those in mitosis, as in previous studies.

Methods

PATIENT POPULATION

Untreated coeliac disease
Eight patients (five men and three women, mean age 43-5 years, range 22-67 years) with histological evidence of coeliac disease from small bowel biopsies which improved subsequently after six months treatment with a gluten free diet according to the modified ESPGAN criteria for diagnosis.9

Treated coeliac disease
Six patients (three men and three women, mean age 46-2 years, range 37-61 years) previously diagnosed with coeliac disease (as above) who had been treated with a gluten free diet for at least six months (mean 11.3 months, range 7-4-26-6 months) with resolution of small intestinal villous architecture.

Control patients
Ten patients (seven men and three women, mean age 37-0 years, range 19-66 years) with morphologically normal small bowel biopsy specimens found in the course of routine diagnostic investigations and who were all eventually found to be suffering from the irritable bowel syndrome.

BIOPSY SPECIMENS
Biopsy specimens were obtained endoscopically from the distal duodenum, orientated, and placed in formalin fixative before being embedded in paraffin wax. Sections were cut at 5 μm thickness on a Leitz Microtome.

PRETREATMENT OF SLIDES
Slides were microwaved before staining as described elsewhere.10 Briefly, slides were placed in pre-warmed 0.01 M tri-sodium citrate solution (pH 6-0) in a glass rack in a microwave proof container, then microwaved at 700 W for 20 minutes, in two lots of 10 minutes with replenishment of the buffer in between. The length of time required for microwaving was titrated, since this varies according to the antigenic epitope and tissue studied. After microwaving, the slides were taken out of sodium citrate solution and placed directly in warm phosphate buffered saline (PBS) before immunostaining.

STAINING OF SLIDES
The primary layer murine monoclonal antibody MI-B1 (The Binding Site, UK) was applied at 1:100 dilution for 35 minutes. The second layer antibody used was rabbit antiserum (Dako E354) at 1:300 dilution for 30 minutes and detection was with streptavidin-peroxidase (Dako 397) at 1:500 dilution for 30 minutes finishing by incubating with DAB for two to three minutes. Sections were washed thoroughly with PBS in between each of the above steps.

ASSESSMENT OF SLIDES

Analysis of staining with MI-B1 antibody
Positively stained cells were counted and expressed as a percentage of the total cells within each vertical crypt cell column and this represented the crypt proliferation index. Enough sections were cut to allow us to analyse at least five (range 5-13, mean 8-6) distinct crypts per patient, and so at least 30 per patient group. Crypts were cut along their longitudinal axis and cells were counted along the left hand side of the column of crypt cells from the base to the mouth of the crypt. Positive cells were easily differentiated from negative cells, and staining was uniform throughout sections. Counts were also assessed blindly by a second observer and the results obtained were correlated. Crypt length was measured as the number of cell units along the left hand column of cells in the crypt, and their position within each crypt length was noted taking the cell at the base of the crypt as position 111 (see Fig 1). Results were expressed with reference to each third of the crypt having divided the total number of cells counted per crypt by three, each third then representing the upper (mouth), middle, and lower (basal) portion (see Fig 1).

Calculation of the crypt growth fraction for each patient group
The definition of growth fraction is a proportion of cells which are engaged in the cell
cycle which, if all cells in the proliferative compartment are cycling, is equivalent to the relative size of the proliferative compartment. Within the crypt column, we calculated the percentage of positively stained crypt cells at each cell position pooled from all patients within each group. This constitutes the proliferative index at that position. Each of these values was then used to construct proliferation index distribution curves for crypts with a length equal to the mean of the appropriate group. The values increase from basal cell positions to a maximum in the proliferative compartment of the crypt and then diminish as the cells leave the cell cycle and enter the maturation compartment at a point called the decycling zone. The growth fraction can be calculated using the theoretical slow cut off model proposed by Cairnie, Lamerton, and Steel, which proposes an increasing probability of a decycling division occurring over a particular portion of the crypt. This point approximates to the cell position at which the proliferation index falls to half of the maximum value (half maximum position) on the trailing edge of the curve and then divided by the mean crypt height.\(^{12-14}\)

**Morphometric analysis**

Enterocyte cell height was estimated by counting cells at approximately one third of the length from the top of a villus using a Leitz microscope with a calibrated eyepiece at \( \times 125 \) magnification.\(^5\) At least three villi and 10 cells per villus were counted randomly and the mean height calculated in micrometres (\( \mu \text{m} \)). Enterocytes were counted throughout each section but not selected from crypts, tips of villi, or areas of obvious morphological distortion (see Fig 1).

**Stereological measurement**

An estimate of villous flattening was made using stereological analysis with a Weibel graticule (Graticules Ltd, Tunbridge Wells, Kent) fitted into a Leitz Westlar microscope eyepiece and counting done at a constant \( \times 125 \) magnification.\(^6\) The number of times lines on the graticule cut the mucosal surface, termed 'cuts' (c) and the number of times the endpoints of the line fell within the covering epithelium and muscularis mucosa, termed 'hits' (h) were noted for each patient. Enough sections were analysed for each patient so that at least 200 'hits' (h) were counted. The length of each line of the graticule at this magnification (l) was found to be \( 1.7 \times 10^{-2} \) cm and the ratio of c/lh calculated. This can be regarded as a measure of small intestinal surface area to volume index (S:V). Previous work has shown that stereology is an accurate method of determining changes in villous flattening.\(^7\)

**CONTROLS**

Sections from human tonsil served as a positive control. Omission of the primary incubating antibody as a negative control.

**STATISTICS**

Statistical analysis of differences between groups was done using the Student's unpaired \( t \) test. Analysis of the correlation between variables was performed by Spearman signed rank correlation. Differences were considered significant if a \( p \) value of less than 5\% was obtained.

**Results**

The results show a significant increase in the duodenal crypt length by counting the number of cells per intact crypt length in untreated coeliac disease when compared with patients with treated coeliac disease and normal controls (\( p<0.05 \) each). There was a significant reduction in the surface to volume index (S:V) and a significant reduction in the enterocyte cell height in the untreated CD group (\( p<0.05 \) each) compared with the other two groups. There was no significant difference in any of these parameters between the treated CD and control groups except for the S:V index which was just significantly less in the treated CD group (\( p=0.049 \)) (see Table 1).

<table>
<thead>
<tr>
<th>TABLE 1</th>
<th>Morphometric and growth fraction analysis of the three patient groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Untreated CD</td>
</tr>
<tr>
<td>Crypt depth (no of cells)</td>
<td>82 (8-3)*†</td>
</tr>
<tr>
<td>Half maximum point (cell pos)</td>
<td>47</td>
</tr>
<tr>
<td>Growth fraction</td>
<td>0.57</td>
</tr>
<tr>
<td>S:V index</td>
<td>13.9 (9-8)*‡</td>
</tr>
<tr>
<td>Enterocyte cell height (( \mu \text{m} ))</td>
<td>14.6 (3-7)*†</td>
</tr>
</tbody>
</table>

*Denotes \( p<0.05 \) compared with the control group, †denotes \( p<0.05 \) compared with the treated CD group, the numbers in brackets represent the standard error of the mean. CD=coeliac disease; S:V index=surface area:volume index.
Analysis of crypt cell proliferation in coeliac disease using MI-B1 antibody shows an increase in growth fraction

Staining with the monoclonal antibody MI-B1 produced a clearly visible brown coloration of crypt cells in cycle which was subjectively greater in the untreated CD group than the other two groups. This staining pattern obtained was evenly distributed throughout each section. Slides were coded and assessed blindly by a second observer and the results obtained by each of them correlated closely (Spearman statistic, 0.92; p=0.003). Using our staining method and length of microwaving specific for gut antigen exposure, little background staining of lymphocytes was found (see Figs 2–4).

The mean percentage of crypt cells which stained positive with the monoclonal antibody MI-B1 was increased not only in the whole of the crypt (see Table II) but significantly raised in the upper, middle, and lower thirds of the crypts when these were divided equally after counting of crypt cells sequentially, thus suggesting the presence of an expanded number of cells in division (Fig 5). This was considered in detail when the size of the proliferative compartment was calculated for each patient group by constructing proliferation index distribution curves (see Fig 6). From these curves the half maximum point was found to be doubled in the untreated CD group (cell position 47) compared with the treated (cell position 24) and control groups (cell position 22). This reflected an increase in growth fraction in the untreated CD group (47/82,0.57) compared with treated CD (24/62,0.39) and control (22/50,0.44) groups.

Importantly there was little difference in any of the proliferation data obtained for the treated CD and control groups.

The increase in individual crypt labelling index correlated very closely with the other known indices of toxicity in CD, namely a reduction in enterocyte cell height and surface area to volume index (Fig 7).

Discussion

Our findings show that the proliferating crypt cell compartment in the untreated CD group covered a greater portion of the expanded crypt. We have been able to quantify this proliferative response using MI-B1. Changes in the crypt proliferation index detected by MI-B1 correlated with the known indices of toxicity in CD, enterocyte cell height and surface area to volume index with crypt proliferation index.

An important observation is that we found an increase in the growth fraction of small intestinal crypts in the untreated coeliac disease group. Previous work involved only the counting of crypt cell mitotic figures and suggested that the growth fraction was decreased in untreated CD due to the massive increase in the total crypt cell population over and above that of crypt cells in the ‘M’ phase of the cell cycle. Our results may have differed because

![Figure 3: An elongated crypt in a patient with untreated coeliac disease. The dark staining (positive) cells extend throughout its length, appearing higher up the crypt than in normal uninflamed tissue (original magnification ×250).](image)

![Figure 4: Small bowel biopsy tissue from a patient with coeliac disease treated with a gluten free diet showing a normal pattern of staining with MI-B1 (original magnification ×250).](image)

<table>
<thead>
<tr>
<th>Untreated CD</th>
<th>Treated CD</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper</td>
<td>45 (3-3)‡</td>
<td>35 (3-0)</td>
</tr>
<tr>
<td>Middle</td>
<td>37 (10-6)</td>
<td>32 (8-1)</td>
</tr>
<tr>
<td>Lower</td>
<td>23 (11-1)</td>
<td>23 (0-9)</td>
</tr>
<tr>
<td>Total</td>
<td>21 (7-5)</td>
<td>19 (7-5)</td>
</tr>
</tbody>
</table>

*Denotes p<0.05 compared with the control group, ‡denotes p<0.05 compared with treated CD group.

CD coeliac disease.
Figure 5: Crypt labelling index per portion of crypt in the three patient groups. There was a significant increase in crypt cell labelling with M1-B1 in all three portions of the crypt in untreated coeliac disease (CD) compared with the treated CD and the control groups. Importantly there was no significant difference in the pattern of staining between the latter two groups. *Denotes p<0.05 compared with control.

Figure 6: Proliferation index distribution curves for the three groups of patients. The distribution of the crypt cell labelling indices for each of the three patient groups are shown. The arrows correspond to the half maximum position for staining which then enables calculation of the growth fraction.

the last mechanism is thought to be of greatest importance. Evidence obtained from studies involving gluten challenge indicate that crypt hyperplasia occurs at an earlier stage to any observed reduction in enterocyte cell height and that the theory implicating enterocyte shedding resulting in stimulation of crypt hyperplasia may not be valid in this disease.20

It has also been shown in an in vitro system that crypt cell hyperplasia and villous flattening can occur without a change in enterocyte cell height.21 However, there is little work which conclusively shows that any specific T cell released factor can cause an increase in crypt cell proliferation in vivo. Work with a fetal organ culture system has shown that stimulating small intestinal mucosal T cells with mitogens, and anti-CD3 in particular, caused crypt cell hyperproliferation and crypt hypertrophy together with apparent villus flattening but when the individual cytokines interleukin 2 (IL 2) and interferon γ were added to the organ culture system these changes could not be reproduced.21

IL 6, a macrophage derived cytokine, and its receptor have recently been shown to be present in increased amounts in human intestinal epithelial cells in some diseases, especially in carcinoma.22 The increase in its production by intestinal epithelial cells is augmented by tumour necrosis factor α, transforming growth factor β (TGF β) and IL 1β,23 which are found in increased amounts in a number of inflammatory enteropathies. It has been shown that IL 6 can up- or down-regulate cell proliferation in a number of systems and that normal and neoplastic intestinal epithelial cells may be autocrinally regulated by it.24

Apart from cytokines, other peptides which have been shown to affect the intestinal epithelial cell proliferative response include growth factors. Epidermal growth factor (EGF) has been shown to be a potent stimulator of epithelial cell production in man,25 as has TGF α, which has a similar but less pronounced effect by binding to the same receptor as EGF.26 TGF β, in addition to increasing the synthesis of IL 6, has been shown to be produced by epithelial cells, which also express its receptor, and it may have a role in directly influencing epithelial cell turnover.27

The mechanism by which crypt proliferation is induced may involve subepithelial mesenchymal cells as they have been shown to have a role in maintaining normal epithelial cell proliferation and differentiation.28

The effects of growth factors and cytokines on small bowel crypt cell proliferation need further study, and this may be achieved by observing their effect on explanted human small intestinal biopsy material in organ culture. An important aim of this study was to document the change in the crypt proliferative pattern and then to assess the ability of growth factors and cytokines to induce these changes on normal small bowel mucosa grown in vitro. These experiments are currently being undertaken by a number of workers.

Hyperproliferation is considered part of the process in the development of carcinogenesis
in tissues. The high rates of proliferation may ‘fix’ damaged DNA before repair is possible. Most gastrointestinal tract tumours arise out of a focal area of dysplasia, a first manifestation of which is a loss of differentiation and an upwards expansion of the proliferative zone such as we found in our untreated CD patients. The picture seen in untreated CD resembles superficially the pattern of proliferation seen in neoplastic epithelium, with the loss of focal areas of regenerative cells and a more expanded uniform population of cells in division. This may be of relevance in a disease in which the incidence of small bowel carcinoma is increased. In ulcerative colitis, studies have shown a failure of the pattern of proliferation to return to normal after remission. However, we found the pattern of proliferation in treated CD to be nearly identical to that in normal tissue. It would be interesting to assess whether this varies with the length of time on a gluten free diet, especially in those at greatest theoretical risk – that is, male or those in whom dietary compliance is poor. It would also be interesting to study archive material from patients with small intestinal cancers to see whether the pattern of proliferation had been more diffuse before the development of cancer when on a gluten free diet.

This work was presented in part as a paper at the British Society of Gastroenterology meeting in Warwick, September 1993. RP acknowledges financial support from the St Thomas’s Hospital Research (endowment) Committee.


